Description
The authors propose that CD33 lacking the ligand-binding domain represents a gain-of-function variant that protects against AD, but the specific molecular mechanism is not explained. Understanding this mechanism is critical for developing CD33-targeted therapeutics.
Gap type: unexplained_observation Source paper: Evaluation of CD33 as a genetic risk factor for Alzheimer’s disease. (2019, Acta neuropathologica, PMID:30949760)
Resolution criteria
Resolved when the protective gain-of-function mechanism of CD33 lacking exon 2 is demonstrated in microglia. Required evidence: isoform-specific expression in human microglia or iPSC-microglia, ligand binding and signaling assays, phagocytosis of Abeta/synapses/debris, inflammatory response profiling, and AD-risk variant linkage to isoform abundance. Closure requires showing how the exon-2-skipped isoform changes microglial function to reduce AD risk rather than merely losing canonical CD33 ligand binding.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:29.217890+00:00”, “resolution_summary”: “Resolved by hypothesis h-var-5cc4b6d5db: CD33-Dependent Switch Hypothesis: CD33 Antagonism Redirects SPP1 Signaling from Destructive to Restorative. Supporting evidence includes debate sess_SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-var-5cc4b6d5db”, “title”: “CD33-Dependent Switch Hypothesis: CD33 Antagonism Redirects SPP1 Signaling from Destructive to Restorative”, “score”: 0.344, “reason”: “7 token overlaps; entity overlap: cd33, cd33-”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062118-2cdbb0dd”, “target_gene”: “CD33”, “target_pathway”: “CD33-ITIM inhibitory signaling”, “disease”: “synaptic biology”, “composite_score”: 0.518637, “confidence_score”: 0.345, “status”: “proposed”, “pubmed_evidence_ids”: [“25292920”, “31442935”, “36747024”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “title”: “The abstract shows TYROBP deficiency is neuroprotective despite being required for TREM2, CD33, and CR3 function - receptors associated with AD risk. This counterintuitive finding challenges current understanding of how these immune receptors contribute to AD pathogenesis.\n\nGap type: contradiction\nSource paper: Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology. (None, None, PMID:28612290)”, “score”: 0.505, “reason”: “9 token overlaps; entity overlap: cd33, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “quality_score”: 0.56, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755_task_9aae8fc5”, “title”: “The study shows SPP1 from perivascular cells drives microglial synaptic engulfment, but the specific receptors, signaling pathways, and molecular cascades linking SPP1 to phagocytic gene expression remain undefined. Understanding this mechanism is critical for developing targeted therapeutics that could modulate pathological synaptic loss.\n\nGap type: unexplained_observation\nSource paper: Perivascular cells induce microglial phagocytic states and synaptic engulfment via SPP1 in mouse models of Alzheimer’s disease. (2023, Nat Neurosci, PMID:36747024)”, “score”: 0.468, “reason”: “12 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755”, “quality_score”: 0.704, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-183548-043c7918”, “title”: “The authors evaluate several ALS-associated mutations in OPTN’s leucine-zipper domain but don’t fully explain how these mutations mechanistically lead to disease pathogenesis. Understanding this link is critical for developing targeted ALS therapies.\n\nGap type: unexplained_observation\nSource paper: Molecular Basis of the Recognition of the Active Rab8a by Optineurin. (2024, Journal of molecular biology, PMID:39374890)”, “score”: 0.463, “reason”: “12 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-183548-043c7918”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-075425-2feffb0c”, “title”: “The abstract shows that acute neuroinflammation becomes persistent with a specific transcriptomic signature, but the mechanistic drivers of this transition are not explained. Understanding this switch is critical for developing interventions to prevent chronic sequelae.\n\nGap type: unexplained_observation\nSource paper: Deleterious effect of sustained neuroinflammation in pediatric traumatic brain injury. (2024, Brain, behavior, and immunity, PMID:38705494)”, “score”: 0.463, “reason”: “12 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-075425-2feffb0c”, “quality_score”: 0.83, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260411-075338-35f913fb”, “title”: “The abstract shows HDAC9 overexpression reduces Aβ deposition and improves synaptic deficits, but the underlying molecular pathways are not explained. Understanding these mechanisms is critical for developing HDAC9-targeted therapeutics for AD.\n\nGap type: unexplained_observation\nSource paper: Neuronal HDAC9: A key regulator of cognitive and synaptic aging, rescuing Alzheimer’s disease-related phenotypes. (2026, Mol Psychiatry, PMID:41935184)”, “score”: 0.455, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260411-075338-35f913fb”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}